Down-regulation of CD98 in melphalan-resistant myeloma cells with reduced drug uptake

Acta Haematologica

Volumn 103, Issue 3, 2000, Pages 144-151

  Harada, Naoko ^a   Nagasaki, Akitoshi ^a   Hata, Hiroyuki ^a   Matsuzaki, Hiromitsu ^a   Matsuno, Fumihiko ^a   Mitsuya, Hiroaki ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

CD98; Drug resistance; Drug transport; Melphalan; Multiple myeloma; Phenylalanine

Indexed keywords

ABC TRANSPORTER; ALKYLATING AGENT; CARRIER PROTEIN; CD98 ANTIGEN; GLUTAMATE CYSTEINE LIGASE; GLYCOPROTEIN P; LEUKOCYTE ANTIGEN; LUNG RESISTANCE PROTEIN; MELPHALAN; MESYLIC ACID ETHYL ESTER; MULTIDRUG RESISTANCE PROTEIN; PHENYLALANINE; RIBONUCLEOPROTEIN; TUMOR ANTIGEN; TUMOR PROTEIN;

ARTICLE; BIOSYNTHESIS; CELL CULTURE; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; MUTAGENESIS; PHYSIOLOGY; STRUCTURE ACTIVITY RELATION; TRANSPORT AT THE CELLULAR LEVEL;

ANTIGENS, CD; ANTIGENS, CD98; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS, ALKYLATING; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CARRIER PROTEINS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ETHYL METHANESULFONATE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMATE-CYSTEINE LIGASE; HUMANS; MELPHALAN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MULTIPLE MYELOMA; MUTAGENESIS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PHENYLALANINE; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 0033642321     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000041037     Document Type: Article

References (33)

1. Vesole DH, Tricot G, Jagunnath S, Desikan KR, Siegel D, Bracy D, Miller L, Cheson B, Crowlcy J, Barlogie B: Autotransplants in multiple myeloma: What have we learned? Blood 1996;88:838-847.
2. Moreau P, Kcrgueris M-F, M ilpied N, Tortorcc SL, Mahe B, Bulabois C-E, Rapp M-J, Larousse C, Batallc R, Harousscau J-L: A pilot study of 220 mg/m2 mclphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: Pharmacokinctics and toxicity. Br J Hacmatol 1996; 95:527-530.
3. Bellamy \VT, Dalton \VS, Gleason MC, Grogan TM, Trent JM: Development and characterization of melphalan-rcsistant human multiple myeloma cell line. Cancer Res 1991;51: 995-1002.
4. Mulcahy RT, Bailey HH, Gipp JJ: Up-rcgulation of Y-glutamylcysteine synthetasc activity in melphalan-rcsistant human multiple myeloma cells expressing increased glutathione levels. Cancer Chcmothcr Pharmacol 1994;34: 67-71.
5. Moscow JA, Swanson CA, Cowan KH: Decreased melphalan accumulation in a human breast cancer cell line selected for resistance to melphalan. Br J Cancer 1993;68:732-737.
6. Eliott EM, Ling V: Selection and characterization of Chinese hamster ovary cell mutants resistant to melphalan (L-phenylalanine mustard). Cancer Res 1981;41:393-400.
7. Redwood \VR, Colvin M: Transport of melphalan by sensitive and resistant LI210 cells. Cancer Res 1980;40:1144-1149.
8. Ahmad S, Okine L, Lc B, Najarian P, Vistica DT: Elevation of glutathione in phenylalanine mustard-resistant murine L1210 leukemia cells. JBiolChcml987;262:15048-15053.
9. Hata H, Matsuzaki H, Sonoki T, Takemoto S, Kuribayashi N, Nagasaki A, Takatsuki K: Establishment of a CD45-positive immature plasma cell line from an aggressive multiple myeloma with high serum lactatc dehydrogenase. Leukemia 1994;8:1768-I773.
10. Thompson LH: Mutant isolation. Methods Enzymol 1979;58:308-322.
11. Gipp JJ, Chang C, Mulcahy RT: Cloning and nucleotide sequence of a full-length cDNA for human liver y-glutamylcysteine synthetasc. Biochem Biophys Res Commun 1992; 185:2935.
12. Cole SPC, Bhardwaj G, Gcrlach JH, Macekic JE, Grant CE, Almquist KC, Stcwart AJ, Kurz EU, Duncan AMV, Declcy RG: Overcxprcssion of a transport gene in a multidrug-rcsistant human lung cancer cell line. Science 1992;258:1650-1654.
13. Cole SPC, Declcy RG: Multidrug resistanceassociated protein: Sequence correction. Science I993;260:879.
14. Schcffer GL, Wijngaard PLJ, Hens MJ, Izquicrdo MA, Slovak ML, Pincdo HM, Meijcr CJLM, Clcvcrs HC, Schpcr RJ: The drug resistance-related protein LRP is the human major vault protein. Nat Mcd 1996;l:578-582.
15. Sugimoto Y, Tsuruo T: DNA-mediatcd transfer and cloning of a human multidrug-rcsistant gene of Adriamycin-resistant myclogenous leukemia K562. Cancer Res 1987;47:2620-2625.
16. Bates DA; Bates JHT: Temperature dependence of melphalan efflux kinetics in Chinese hamster ovary'cells. Biochem Pharmacol 1991; 41:1173-1177.
17. Hâta H, Matsuzaki H, Takcya M, Yoshida M, Sonoki T, Nagasaki A, Kuribayashi N, Kawano F, Takatsuki K: Expression of Fas/Apo-1 (CD95) and apoptosis in tumor cells from patients with plasma cell disorders. Blood 1995;86:1939-1945.
18. Miyashita T, Reed JC: Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993;81:151-157.
19. Stefan B, Angelika B, Brcnd H: The 4F2hc surface antigen is necessary for expression of system L-like neutral amino acid transport activity in C6-BU-1 rat glioma cells: Evidence from expression studies on Xenopus laevis oocytcs. Biochem J 1995;312:863-870.
20. Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H: Expression cloning and characterization of a transporter for large neutral amino acid activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 1998;273:23629-23632.
21. Dalton WS, Duric BGM, Alberts DS, Gcrlach JH, Cress AE: Characterization of a new drugresistant human myeloma cell line that express P-glycoprotein. Cancer Res 1986;46:5125-5130.
22. Wylcr B, Shao Y, Schneider E, Cianofriglia M, Scheper RJ, Frey BM, Gicsclcr F, Schmid L, Twcntyman PR, Lchncrt M: Intermittent exposure to doxorubicin in vitro selects for multifactorial non-P-glycoprotein-associated multidrug resistance in RPMI 8226 human myeloma cells. BrJ Haematol 1997;97:65-75.
23. Linscnmcycr ME, Jefferson S, Wolf M, Matthews JP, Board PG, Woodcock DM: Levels of expression of the mdrl gene and glutathione Stransfcrase genes 2 and 3 and response to chemotherapy in multiple myeloma. Br J Cancer 1992;65:471-475.
24. Raaijmakcrs HGR, Izquierdo MAI, Lokhorst HM, de Lccuw C, Bclicn JAM, Blocm AC, Dekkcr AW, Scheper RJ, Sonnevcld P: Lungresistancc-rclatcd protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma. Blood 1998;91:1029-1036.
25. Tu Y, Renner S, Xu F, Flcishman A, Taylor J, Weisz J, Vescio R, Rettig M, Berenson J, Krajcwski S, Rced JC, Lichtenstein A: BCL-X expression in multiple myeloma: Possible indicator of chemorcsistancc. Cancer Res 1998;58: 256-262.
26. Friesen C, Herr I, Krammcr PH, Debatin KM: Involvement of the CD95 (Apo-1/Fas) receptor/Iigand system in drug-induced apoptosis in leukemia cells. Nat Med 1996;2:574-577.
27. Friesen C, Fulda S, Debatin KM: Deficient activation of CD95 (Apo-1/Fas) system in drug-resistant cells. Leukemia 1997;11:1833-1841.
28. Fluda S, Sicvcrts H, Friesen C, Herr I, Debatin KM: The CD95 (Apo-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 1997;57:3823-3829.
29. Kuribayashi N, Hata H, Yoshida M, Sonoki T, Nagasaki A, Kimura T, Harada N, Matsuzaki H: Establishment and characterization of a CD95 (Fas/Apo-I)-ncgative myeloma cell line. ActaHaematoll999;101:113-118.
30. Goldenberg GJ, Lee M, Lam HYP, Begleiter A: Evidence for carrier-mediated transport of melphalan by L5178Y lymphoblasts in vitro. Cancer Res 1977;37:755-760.
31. Begleiter A, Lam HYP, Grovcr J, Froese E, Goldcnbcrg GJ: Evidence for active transport of melphalan by two amino acid carriers in L5178Y lymphoblasts in vitro. Cancer Res 1979;39:353-359.
32. Goldcnbcrg GJ, Lam HYP, Begleiter A: Active carrier-mediated transport of melphalan by two separate amino acid transport systems in LPC-1 plasmacytoma cells in vitro. J Biol Chcm 1979;254:1057-1064.
33. Mastrobcrardino L, Spindlcr B, Pfciffer R, Skelly PJ, Lofting J, Shoemaker CB, Verrey F: Amino-acid transport by hcterodimcrs of 4F2hc/CD98 and members of a permease family. Nature 1998;395:288-291.